Compare BRAG & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRAG | VERU |
|---|---|---|
| Founded | 2018 | 1971 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8M | 41.9M |
| IPO Year | 2021 | 1996 |
| Metric | BRAG | VERU |
|---|---|---|
| Price | $1.16 | $2.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.30 | ★ $25.67 |
| AVG Volume (30 Days) | 10.1K | ★ 206.4K |
| Earning Date | 11-12-2026 | 08-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $2.05 |
| 52 Week High | $2.80 | $7.33 |
| Indicator | BRAG | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 43.80 |
| Support Level | N/A | $2.11 |
| Resistance Level | $1.82 | $2.40 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 9.55 | 28.13 |
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from Malta, and the rest from Netherlands, Curacao, the United States, Croatia, Marshall Islands, Brazil, Isle of Man, Belgium, Czech Republic, and other regions.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.